A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Latest Information Update: 28 Apr 2023
Price :
$35 *
At a glance
- Drugs Roxadustat (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Proof of concept; Therapeutic Use
- Acronyms WHITNEY
- Sponsors FibroGen
- 01 May 2023 Results published in the American Journal of Hematology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 25 Aug 2021 According to a FibroGen Media Release, the full results of the study will be presented at a medical meeting later this year.